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Background: Successful response to repetitive transcranial magnetic stimulation (rTMS) 
of the motor cortex requires continued maintenance treatments. Transcranial Direct Current 
Stimulation (tDCS) may provide a more convenient alternative.
Methods: This pilot study aimed to examine the feasibility of a randomized, double-blind, 
double-crossover pilot study for patients to self-administer tDCS motor cortex stimulation for 
20 minutes/day over five consecutive days. Primary outcomes were as follows: usability of 
patient-administered tDCS, compliance with device, recruitment, and retention rates. Secondary 
outcomes were as follows: effect on overall pain levels and quality of life via Short Form-36 
anxiety and depression via Hospital Anxiety and Depression Scale, and Mini-Mental State scores.
Results: A total of 24 subjects with neuropathic pain, who had previously experienced rTMS 
motor cortex stimulation (13 with reduction in pain scores, 11 nonresponders) were recruited 
at the Pain Research Institute, Fazakerley, UK. A total of 21 subjects completed the study. 
Recruitment rate was 100% but retention rate was only 87.5%. All patients reported satisfactory 
usability of the tDCS device.
No significant difference was shown between Sham vs Anodal (–0.16, 95% CI: –0.43 to 
0.11) P=0.43, Sham vs Cathodal (0.11, 95% CI: –0.16 to 0.37) P=0.94, or Cathodal vs Anodal 
(–0.27, 95% CI: –0.54 to 0.00) P=0.053 treatments. Furthermore, no significant changes were 
demonstrated in anxiety, depression, or quality of life measurements. The data collected to 
 estimate sample size for a definitive study suggested that the study’s sample size was already 
large enough to detect a change of 15% in pain levels at 90% power for the overall group of 
21 patients.
Conclusion: This study did not show a beneficial effect of tDCS in this group of patients and 
does not support the need for a larger definitive study using the same experimental paradigm.
Trial registration: ISRCTN56839387
Keywords: neuropathic pain, brain stimulation, motor cortex, M1, transcranial direct current 
stimulation, tDCS, transcranial magnetic stimulation, TMS
Introduction
Stimulation of the primary motor cortex (M1) has been shown to be effective in the 
treatment of chronic neuropathic pain.1 Early studies of neuromodulation for relief of 
chronic pain demonstrated the benefit of direct electrical stimulation using electrodes 
surgically implanted on the surface of the brain.2,3 However, given the invasiveness 
of this technique and the risk of complications and expense, it has not been widely 
adopted. One promising area of research on the treatment of chronic pain involves 
applying noninvasive brain stimulation techniques, which may act to modulate 
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abnormal processes associated with this condition. These 
techniques include repetitive transcranial magnetic stimu-
lation (rTMS) and transcranial direct current stimulation 
(tDCS). Although the results for rTMS therapy in chronic 
pain appear promising,4,5 its clinical use is limited by the 
short duration of action, necessitating frequent repeat treat-
ment sessions, thus raising issues of service capacity and 
patient compliance. Indeed, a more common practice is to 
use TMS as a screening method for invasive epidural motor 
cortex stimulation.6,7
TMS involves placing a coil over the scalp through which 
an electric charge is passed, generating a magnetic field, 
which can induce an electric pulse in the brain sufficient 
to activate cortical neurons. When appropriate patterns or 
trains of pulses are used, it results in modulation of activity 
of cortical circuitry,8 which can be excitatory or inhibitory. 
Importantly, rTMS can affect the excitability of brain regions 
distant to the target site through synaptic connections to func-
tionally related brain regions.9 This is thought to explain why 
motor cortex stimulation has an analgesic effect in chronic 
neuropathic pain. tDCS does not directly activate cortical 
neurons but rather affects their excitability via modulation of 
resting membrane potential.10 Anodal stimulation increases 
excitability of affected neurons and cathodal stimulation 
reduces excitability.11 Studies of anodal tDCS of the M1 
motor cortex in fibromyalgia, pelvic pain, multiple sclerosis, 
and cancer pain, and phantom limb patients have been mostly 
positive,12–17 while those in neuropathic pain as a result of 
spinal cord injury have been mixed.18–23
We wished to establish the efficacy of using a patent’s 
response to motor cortex rTMS as a screening method 
for tDCS designed for home-based use and to assess the 
feasibility and efficacy of using home-based tDCS therapy 
in two groups of neuropathic pain patients (responders vs 
nonresponders to rTMS).
The plan was to design a definitive trial to test whether 
tDCS over the M1 cortex reduces pain scores in subjects 
known to have previously gained relief from high-frequency 
rTMS of primary motor cortex. Our hypothesis was that 
rTMS responders would derive greater benefit from anodal 
tDCS than nonresponders. Furthermore, we postulated that 
there would be no difference between responders and nonre-
sponders in pain relief from cathodal or sham tDCS.
As this study design includes the use of patient-delivered 
tDCS, a pilot study was necessary to examine the practicality 
of this approach.
The aims of this pilot study were to test whether tDCS 
over M1 area could be manageably delivered by patients or 
carers at home, and to test recruitment and retention rates 
for this study design.
The study design also collected outcome data on average 
weekly pain scores, quality of life via Short Form-36 (SF-36), 
anxiety and depression via Hospital Anxiety and Depression 
Scale (HADS), and Mini Mental State Examination (MMSE) 
to assess for cognitive changes. These assessments will form 
the primary and secondary outcomes of the full trial. These 
data will be used to inform sample size calculations for future 
study. Overall data will be used to identify challenges in the 
study conduct.
Methods
study participants
All participants had previously taken part in a clinical trial 
examining effect of rTMS motor cortex stimulation in chronic 
pain.24 As subjects were recruited from this study pool, their 
response to previous treatment with rTMS for chronic pain 
was known.
inclusion criteria
1) Age between 18 and 85 years old. 2) Diagnosis of uni-
lateral neuropathic pain as defined by the International 
Association for the Study of Pain Special Interest Group 
on Neuropathic Pain.25 3) Stable analgesic medication for 
prior month. 4) Average pain levels >4 out of 10 on numeri-
cal rating scale (NRS) for pain during the 1-week run-in 
phase, based on patient diary. 5) Willingness to take part 
in the study and ability to give consent. 6) Previously had a 
minimum of 5 sessions of rTMS for pain, and can be named 
as a “responder” or “nonresponder”. Responder: reporting 
a weekly average pain reduction of a minimum of 15% on 
an NRS of 0–10, following five rTMS sessions. This was 
chosen as the minimally important change in pain scores 
as defined by the Initiative on Methods, Measurement, 
and Pain Assessment in Clinical Trials consensus recom-
mendations.26 7) Subjects were required to have had pain 
for >6 months.
exclusion criteria
1) Pain of other origin, for example, musculoskeletal pain as 
this could interfere with the reporting of the neuropathic pain 
being targeted. 2) Metal implants/coils/electronic devices. 3) 
Drug or alcohol abuse. 4) Pregnancy. 5) Psychiatric or psy-
chological disorders. 6) Epilepsy. 7) Inability to understand 
instructions or operate equipment. 8) High-dose opioids. 9) 
Uncontrolled medical conditions (eg, active cancer, uncon-
trolled renal, pulmonary, or cardiac disease, etc).
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The study was carried out at the Pain Research Institute, 
Clinical Sciences Center, Fazakerley, Liverpool, UK.
This study was conducted in accordance with the Dec-
laration of Helsinki. Ethics approval was obtained from 
the national ethics committee (NRES REC reference 12/
EE/0315), and all subjects gave informed written consent to 
participate in the study.
study design
A randomized, double-blind, double-crossover design was 
used so that all subjects participated in both anodal and 
cathodal active treatments (tDCS) and sham treatment (Trial 
registration: ISRCTN56839387). The treatment sequence 
was randomized and counterbalanced and the subjects and 
the response assessor were blinded to it.
assessment of recruitment and retention rates
Assessment of pain and other pain-related variables occurred 
at initial assessment, for 14 days starting at and including 
each 5-day period of intervention, and at 4-week follow-
up (after a minimum 2-week period for washout). Stable 
medication use before and during the trial was required. The 
randomized crossover design is shown in Figure 1 (Consort 
Flowchart27,28). The study protocol has been published previ-
ously.24 No changes to the protocol were made.
interventions
We wished to optimize patient selection to those patients 
who had previously undergone mapping of the motor cortex 
using brain navigation TMS localization, and therefore, had a 
known degree of cortical reorganization, with optimal coor-
dinates for each participant available to guide the placement 
of tDCS electrodes on the scalp.
Identification of motor cortex stimulation site
As subjects had previously been enrolled in a TMS study 
evaluating the impact of target location on pain relief, they 
had undergone MRI of the brain and mapping of the motor 
cortex.24 All participants had undergone a trial of two separate 
locations within M1, contralateral to their pain, and the loca-
tion of the active tDCS electrode was placed over the site at 
which the best rTMS response was obtained.24
tDcs treatment
tDCS used was similar to that described previously18 but sub-
jects were instructed how to administer the stimulation them-
selves. For each active treatment, one 20-minute session was 
delivered each day for five consecutive days. A 4-week period 
occurred between each treatment type (active and sham). Direct 
current was applied to the scalp by a commercial tDCS unit 
using a pair of saline-soaked sponge-covered surface electrodes 
(HDCstim, Newronika s.r.l., Milan, Italy). This system has a 
maximum stimulation setting of 1.5 mA and proprietary-sized 
electrodes (25 cm2, 5 × 5 cm). A current of 1.4 mA (30 second 
ramp on) was delivered, giving a current density of 0.056 mA/
cm2, which is comparable to previous studies.
During active tDCS treatment, subjects received stimula-
tion of the primary motor cortex (M1). For anodal stimula-
tion, the anode electrode was placed over the previously 
identified “hotspot” during TMS mapping and the cathode 
electrode over the contralateral supraorbital area. For cathodal 
stimulation, the electrodes were reversed. Stimulation was 
applied to the opposite hemisphere to the side in which the 
dominant neuropathic pain was felt.
Patient-administered stimulation
At the initial visit, measurements were taken for individually 
fitted headband locators to facilitate electrode placement. Once 
fitted, subjects were shown how to position the headbands 
reproducibly and asked to demonstrate this to the investigator. 
Photographs and measurements were taken by the patients in 
case of the need for reference at home. Electrode placement 
was checked at the beginning of each treatment block.
Patients were administered a constant current of 1.4 mA 
for 20 minutes daily for 5 days at the same time of the day. 
All subjects were asked to remain non-active during this 
time and engage in either light reading/watching television 
or listening to the radio.
assessment of usability of device
Patients were asked to record the ease of use of their tDCS 
device setup and report if they had any difficulties with elec-
trode placement or device use. Each device kept an internal 
record of the number of times the device was used and an 
exact record of the date, time of day, and duration the device 
was used for. It also recorded the current and average resis-
tance during each stimulation. This allowed the investigator 
to track the use of the device.
assessment of device compliance
interrogation of tDcs devices
Individual stimulators were interrogated after each 5-day period 
of use to check correct stimulation delivery. The device records 
the number of stimulations delivered, the time and date of 
stimulation, and the stimulation parameters, including current 
strength, duration of stimulation, and resistance of circuit in 
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ohms. It also recorded if any error occurred during stimulation, 
eg, if stimulation was aborted. This allowed full assessment 
of device compliance with each patient and treatment block.
sham intervention
For sham stimulation, the electrodes were placed in the 
same positions as that for anodal M1 stimulation; however, a 
constant current of 1.4 mA was delivered only for 5 seconds 
(30-second ramp on). This sham delivery is pre-programmed 
into the device and automatically stops at the correct time 
period. The settings on the device visible to the patient are 
indistinguishable from active treatment settings. A count-
down timer on the display panel will continue to count down 
over 20 minutes and the patient then removes the device. 
During active tDCS treatment, subjects typically report tin-
gling sensations under the electrodes, which rapidly fade.29 
Invited to participate and 
satisfy inclusion criteria
(N=24)
Randomization and allocation 
to treatment sequence
(N=24)
A
N=4 
Treatment
5 days
Pain scores 
for 2 weeks
Follow-up (N=21)
Satisfied with treatment
(N=2)
Not satisfied with 
treatment (N=19)
A
N=2 
B
N=4 
A
N=3 
A
N=5 
A
N=4 
A
N=4 
B
N=4 
B
N=2 
B
N=3 
B
N=4 
B
N=4 
C
N=3 
C
N=4 
C
N=4 
C
N=2 
C
N=5 
C
N=6 
Withdrawal from 
study (N=2)
Withdrawal from 
study (N=1)
Lost to follow-up
(N=0)
Allowed to continue with most 
appropriate stimulation on open label 
basis (N=2)
Baseline measurement (1 week)
Washout
2 weeks
Washout
2 weeks
Washout
2 weeks
Stimulation sequence
1 52 3 4 6
C
A
B
Key
= Anodal
= Cathodal
= Sham
Study start
Treatment
5 days
Pain scores 
for 2 weeks
Treatment
5 days
Pain scores 
for 2 weeks
Figure 1 cOnsORT Flowchart. 
Note: Trial design, including participant flow and dropouts, showing 24 subjects recruited and randomized with a total of 3 withdrawals from the study, giving 21 subjects 
at follow-up.
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Our sham intervention was, therefore, designed to provide 
an initial period of tingling so that similar sensations were 
perceived during active and sham tDCS protocols. This sham 
protocol has been used by previous investigators.18,30
Randomization and blinding
Subjects were randomized in two ways. First, each stimula-
tion device was assigned a random treatment order. Second, 
each subject was assigned to a random device number. Both 
these tasks were completed by a researcher (unrelated to the 
study) by picking the folded paper containing the treatment 
order/subject order from an urn. This order was written 
down as a master key and divided into two study keys. A 
research assistant (not otherwise related to the study) set 
the  stimulation parameters as indicated by the first study 
key, and was aware of the treatment order each device was 
programmed for but was unaware which subject received 
each device.
The investigator was aware which device to give to each 
subject by following the second study key but was unaware 
of the treatment order programmed in that device. The master 
randomization key was kept in a sealed envelope.
Subjects were not directly informed that a sham stimula-
tion was being used. Rather they were told that three different 
types of stimulation treatments would follow each other, some 
of which may or may not feel different.
Only at the end of the study were subjects informed 
that a sham stimulation was one of the treatments. At this 
time, they were asked verbally if they were able to guess the 
order of stimulation. Their guess was checked against the 
randomization key.
Assessments
Primary outcome measures
Usability of patient-administered tDcs
The ease of use of the tDCS setup for patient administration 
was assessed by a patient experience questionnaire. This 
included four questions: 1. Did you feel the device was easy 
to use? 2. Did you have any problems using the device? 3. 
Did you have to contact a member of the research team for 
advice about using the machine while at home? 4. Did you 
have to abandon using the device for any reason?
Patient compliance with device
As patients may have felt the device was easy to use but 
still have used it incorrectly, compliance with the device 
was assessed. This was done by a combination of device 
interrogation to discern the timing, number, and duration 
of stimulations delivered during use and if any errors had 
occurred. Also, at return appointments, patients were asked 
to demonstrate the positioning of the electrode placements to 
ensure that they were complying with the correct anatomical 
positioning.
Recruitment and retention
A record was kept of the number of patients recruited and 
the date they joined the study. Also, the number, timing, and 
reasons for any patient withdrawals from the study were 
documented.
secondary outcome measures
Effect on overall pain was assessed on an 11-point (0–10) 
NRS questionnaire. Patients were asked to complete these 
at home each night based on the average pain scores over 
the previous 24 hours. Pain diaries were returned at the next 
patient visit.
Subjects completed the following questionnaires at base-
line and at the end of each treatment period: SF-36 to assess 
quality of life, HADS to assess anxiety and depression, and 
MMSE to assess for cognitive changes. Patients were also 
asked to complete a questionnaire regarding any difficulties 
encountered in using the device during the trial.
statistics
sample size
For this pilot study, the sample size was based on an oppor-
tune sample of 24 patients who had previously undergone 
rTMS and expressed willingness to take part in the study. 
No formal power calculations were carried out prior to the 
study. Results from this study have been used to calculate a 
definitive sample size from the recorded effect size and SDs 
of the observed data. This is reported in the discussion at the 
end of this paper.
statistical analyses
Simple descriptive statistics were used to describe the primary 
outcomes and adverse events.
To investigate the effect of the three modes of stimula-
tion on the secondary outcomes of interest, a linear mixed 
effects model was used. The mode of tDCS, treatment 
period, responder group, and time were all regarded as fixed 
effects, and the patient (nested in sequence) as the random 
effect. Three time points were used when measuring daily 
pain intensity; days 1, 5, and 14, which corresponded to the 
beginning and end of treatment, and the end of the observa-
tion period, respectively. The mean of the 7-day baseline pain 
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diary was used as baseline for the first mode of treatment. As 
a baseline pain diary was not completed before each tDCS 
treatment period, the pain score recorded on the first day of the 
observation period was taken as the baseline measurement for 
the second and third treatment. A one-way ANOVA test was 
implemented on these measurements to ensure that they did 
not differ significantly between treatments. As the secondary 
outcomes – HADS and SF-36 – were only measured once 
for each treatment, a time component was not included as a 
fixed effect when analyzing them.
For sensitivity analysis, baseline and clinical measure-
ments were added one by one to the model and those that 
altered the results significantly were included. A treatment by 
period interaction was investigated to see whether there was a 
difference in pain according to the sequencing of treatments.
The association between tDCS and rTMS responders was 
investigated using Fisher’s exact test. A tDCS responder was 
classified as a pain reduction from baseline of at least 15%.
All analyses were performed using Stata version 13 
(StataCorp. 2013. Stata Statistical Software: Release 13. 
College Station, TX, USA: StataCorp LP).
Results
Patient demographics
A total of 24 subjects (nine female, 15 male) with unilateral 
neuropathic pain were recruited for this study between Octo-
ber 2012 and August 2014. Of those recruited, 13 (54%) were 
prior responders to rTMS treatment. The mean duration of 
pain was 8.04±4.9 years (Table 1).
Primary outcomes
Recruitment and retention rate
The target number of patients was recruited within the allotted 
time period. Although the study required several attendances 
at the research unit and also required multiple treatment 
sessions, only three patients (12.5%) dropped out, with a 
retention rate of 87.5%.
losses and exclusions
One subject was excluded from the analysis as the patient 
failed to complete/return any pain diaries within the time 
frame of the study; the subject completed the randomized 
treatment. Two patients withdrew from the study; one with-
drew after the first sham trial due to an exacerbation of pain 
and one withdrew after one sham trial and one failed cathodal 
trial, reporting difficulty in accommodating treatment ses-
sions with daily schedule. One subject returned an incomplete 
pain diary for the sham trial and one subject returned an 
incomplete diary for the cathodal trial and failed to return 
one for the anodal trial.
Usability of patient-administered tDcs
All patients reported the device was easy to use with a general 
appreciation of the convenience of home-based stimulation. 
This reflects the simplicity of this particular model of tDCS 
device with a simple on/off switch and start button. Position-
ing of headbands was not considered a problem. All subjects 
said that the positioning marking on the headbands was easy 
to follow and positioning was easy to replicate. Two subjects 
with single limb paralysis even reported being able to position 
the headbands one handedly, although they usually received 
help from a relative for speed. One subject reported that the 
headband would slip during use, which required readjust-
ment. One subject who did not return any pain diaries dur-
ing the study did not report any problems using the device. 
Another subject felt that although the device itself was easy 
to use, the time required for treatment sessions, that is, 20 
minutes for stimulation and ~10 minutes setup time was 
difficult to fit in with daily activities.
The main issue affecting compliance was that if there was 
unsatisfactory contact between the electrode and skin, then 
the current circuit was broken and the device would abort the 
stimulation. This was usually easily rectified by re-wetting 
of the electrode sponge; however, the patient would need to 
start a different stimulation session. In practice, when this 
happened, an extra stimulation was delivered if the patient 
noticed but if it went unnoticed, an aborted stimulation was 
recorded on the device log.
Seven patients (29%) reported that they had to contact the 
research team for advice regarding this issue. All issues were 
resolved via a telephone conversation. Two patients (8%) did 
not notice a signal failed stimulation; this was subsequently 
identified on interrogation of the device log. No subjects had 
to totally abandon using the device.
Patient/device compliance
The actual number of stimulations self-administered by sub-
jects per trial is shown in Table 2. In total, 72 trials comprising 
of five stimulations per trial were planned over the course of 
the study. Of these 72 trials, six were not completed due to 
three subject withdrawals and ten were completed differently 
from the protocol. Of the ten trials not completed as directed, 
four of the five stimulations were delivered in six trials and in 
one trial, three stimulations were delivered. In the remaining 
three trials, extra stimulations were recorded due to either 
a failed or aborted activation of the device and the patient 
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subsequently delivering further stimulations to reach the full 
five stimulations as per protocol. Only two subjects guessed 
the randomization sequence correctly, while most said that 
they would be unable to guess.
adverse events
A total of 16 (62%) subjects reported tingling of the fore-
head/scalp and 12 (50%) reported redness after treatment, 
both during active and sham stimulations. Two (8%) reported 
tiredness. One subject reported a sharp increase in pain after 
sham stimulation and withdrew from the study. Five (20%) 
subjects reported headache following treatment, which 
lasted for ~2 hours and occurred in both active and sham 
stimulations. Two (8%) patients reported an exacerbation 
of parathesia experienced in the affected area at 4-week 
follow-up.
secondary outcomes
Overall pain intensity
Numerical pain rating scores for each treatment over time are 
summarized in Table 3. Comparison of baseline pain scores 
showed no significant difference between the three treatment 
arms (one-way ANOVA, P=0.9941).
Table 1 individual patient characteristics
Subject ID Sex Diagnosis Central or 
peripheral pain
Pain duration 
(months)
Response 
to rTMS
Pain medication
a F Spinal cord injury central 8 R gabapentin
B M Phantom limb pain Peripheral 20 R gabapentin
c M central post stroke pain central 9 R none
D M Spinal cord injury central 10 R none
e M cRPs type ii Peripheral 12 R none
F F Phantom limb pain Peripheral 3 nR gabapentin
g M central post stroke pain central 11 R none
h M Brachial plexus avulsion Peripheral 13 nR none
i M central post stroke pain central 6 nR gabapentin
J M central post stroke pain central 7 R Pregabalin
K M neuropathic pain right leg Peripheral 13 R Pregabalin
l M central post stroke pain central 2 nR none
M F Brachial plexus avulsion Peripheral 4 nR Pregabalin
n F Radiculopathy left hand Peripheral 3 R Pregabalin
O M central post stroke pain central 11 nR none
P M Trigeminal neuropathy Peripheral 2 nR Pregabalin
Q F Trigeminal neuropathy Peripheral 20 nR Pregabalin
R F Trigeminal neuropathy Peripheral 7 nR none
s M central post stroke pain central 6 nR none
T F central post stroke pain central 4 R lamotrigene
U F Trigeminal neuropathy Peripheral 5 R gabapentin
V F central post stroke pain central 4 nR Pregabalin
W M neuropathic pain left arm Peripheral 7 R Pregabalin
X M Trigeminal neuropathy Peripheral 6 R lamotrigene
Mean ±sD (8.04±4.98)
Note: Patients were classified as having neuropathic pain of either central or peripheral nerve origin based on diagnosis. Responders to rTMS had a reduction in pain intensity 
during the previous rTMs study. 
Abbreviations: R, responder; nR, non-responder; rTMs, repetitive transcranial magnetic stimulation.
Table 2 number of stimulations delivered per trial completed 
for each subject
Subject ID Anodal Cathodal Sham
a 0 0 5
B 5 5 5
c 5 5 5
D 0 0 5
e 5 5 4
F 5 5 5
g 4 5 5
h 5 5 7
i 5 5 5
J 5 5 6
K 5 5 5
l 5 5 5
M 5 5 5
n 0 0 5
O 5 5 5
P 3 4 5
Q 5 5 5
R 5 5 5
s 5 5 4
T 5 6 5
U 4 5 5
V 5 5 5
W 5 4 5
X 5 5 5
Notes: Target number of five stimulations per trial.
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A linear mixed model was fitted to the data and the 
treatment-by-day and treatment-by-period interactions were 
investigated. There was no significant difference in overall 
pain between treatments (Figure 2); Sham vs Anodal (–0.16, 
95% CI: –0.43 to 0.11, P=0.43), Sham vs Cathodal (0.11, 
95% CI: –0.16 to 0.37, P=0.94), or Cathodal vs Anodal 
(–0.27, 95% CI: –0.54 to 0.00, P=0.053). No significant dif-
ference was seen between mean pain scores on day 1, 5, or 
14 for any treatments; day 5 vs day 1 (0.13, 95% CI: –0.13 
to 0.38, P=0.625), day 14 vs day 1 (–0.04, 95% CI: –0.29 to 
0.22, P=0.788), and day 14 vs day 5 (–0.16, 95% CI: –0.42 
to 0.10, P=0.216). No carryover effects were present.
haDs and sF-36
Mean values of anxiety and depression scores are shown in 
Table 4.
anxiety
Effects on anxiety and depression scores are summarized 
in Table 5. Anxiety was reduced in treatment period three 
regardless of treatment modality (difference 1.20, P=0.014) 
and also showed a greater reduction with increased number 
of stimulations (–1.45, 95% CI: −2.34 to –0.56, P=0.002). 
However, the effect from the number of stimulations could 
be spurious as 85% of the trials recorded five simulations. 
There was an imbalance in mean levels of anxiety within 
the sequences. The average anxiety for sequence Cath-
odal–Anodal–Sham was much higher than that for the other 
sequences at baseline and throughout, while the mean for 
sequence Sham–Anodal–Cathodal was lower than the rest.
Depression
No differences were seen in depression between treatment 
modalities.
sF-36
Analysis of effect on two summary domains of patient-
reported health outcomes in the SF-36 questionnaire Physi-
cal Component Summary (PCS) and Mental Component 
Summary (MCS) showed that tDCS treatment had no effect 
on PCS or MCS. An increase in the number of stimulations 
was associated with an increased MCS (4.69, 95% CI: 1.07 
to 8.31, P=0.013).
Proportion analysis
The three treatment groups were divided into two categories 
according to the reduction in pain on the fourteenth day and 
Fisher’s exact test was used to find any association between 
rTMS and tDCS responders. No relationship was found.
Discussion
This study, in which a cohort of chronic pain patients who 
had previously undergone treatment with rTMS were trialed 
with anodal, cathodal, and sham tDCS stimulation, failed to 
demonstrate a beneficial effect of tDCS in this group. This 
suggests that even in patients who respond well to rTMS to 
the motor cortex, substitution of TMS for tDCS motor cortex 
stimulation is not as suitable as anticipated, at least not in 
this group of patients and with this electrode configuration. 
It has, however, demonstrated that recruitment, retention, and 
compliance within this study design are feasible.
limitations
compliance
Patients were asked to perform self-administered tDCS 
stimulation at home. As stimulation was not directly observed 
by a researcher, variation in electrode placement may have 
taken place. However, when asked to complete a question-
naire on ease of use of the tDCS device, none of our subjects 
reported placement of electrodes to be an issue. All subjects 
were individually fitted with measured headbands to securely 
hold electrodes and shown how to reproducibly locate them.
The analgesic effect of tDCS may be cumulative with 
greatest effect after 5 days of treatment.12,18 We cannot 
exclude that the seven trials in which fewer than five consecu-
tive days of tDCS stimulations were delivered could have 
Table 3 analysis of effect of tDcs on overall pain
Overall pain score
Anodal Cathodal Sham
Day N Mean SD N Mean SD N Mean SD
Baseline 20 6.43 1.71 21 6.19 1.68 23 6.48 1.83
Day 1 19 6.45 1.76 20 6.40 1.78 23 6.43 1.67
Day 5 18 6.53 1.70 21 6.43 1.73 23 6.70 1.53
Day 14 20 6.10 1.72 19 6.42 1.62 22 6.45 1.90
Note: No significant difference between baseline values of each treatment P=0.99 (one-way anOVa) or in numerical rating scale mean values between sham vs anodal 
(–0.16, 95% CI: –0.43 to 0.11) P=0.43, Sham vs Cathodal (0.11, 95% CI: –0.16 to 0.37) P=0.94, or Cathodal vs Anodal (–0.27, 95% CI: –0.54 to 0.00) P=0.053.
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Table 4 Adverse events for each type of stimulation for each individual subject. 
Subject 
ID
Anodal Cathodal Sham At Follow-up
a none none none none
B Tiredness Tiredness Tiredness none
c none none none exacerbation of paresthesia 
in the affected area
D none none increase in pain none
e Tingling/redness Tingling/redness Tingling/redness none
F Tingling/redness Tingling/redness Tingling/redness none
g headache headache headache none
h Tingling/redness Tingling/redness Tingling/redness none
i Tingling/redness Tingling/redness Tingling/redness none
J Tingling/redness/headache Tingling/redness/headache Tingling/redness/headache none
K none none none none
l Tingling/redness/headache Tingling/redness/headache Tingling/redness/headache Tingling/redness/headache
M headache headache headache none
n none none Tingling/redness none
O Tingling Tingling Tingling none
P Tingling Tingling Tingling none
Q Tingling/redness Tingling/redness Tingling/redness none
R Tingling/tiredness Tingling/tiredness Tingling/tiredness none
s Tingling/redness Tingling/redness Tingling/redness none
T Tingling/redness Tingling/redness Tingling/redness none
U Tingling/redness Tingling/redness Tingling/redness exacerbation of paresthesia 
in the affected area
V Tingling/redness Tingling/redness Tingling/redness none
W Tingling Tingling Tingling none
X headache headache headache none
Notes: each of the three patients who reported symptoms at follow-up subsequently reported resolution within a further 3 months.
4
5
6
7
8
9
Treatment
Anodal
Cathodal
Sham
Mean (95% CI) of overall pain scores
M
ea
n 
ov
er
al
l p
ai
n
Day 1 Day 5 Day 14
Figure 2 effect of tDcs on overall pain scores.
Note: X-axis= time in days from start of treatment session. Y-axis= mean pain scores on 11-point (0–10) numerical pain rating scale with (95% CIs). No significant differences 
were observed between sham, anodal, or cathodal stimulations.
Abbreviation: tDcs, transcranial direct current stimulation.
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reduced any overall effect, but no clear trend was observed 
in the study.
generalizability
Is there a possibility that prior exposure to rTMS could 
have affected subsequent response to tDCS? While interac-
tion of these two different forms of stimulation has been 
documented,31,32 these findings have been in relation to tDCS 
priming prior to TMS. Furthermore, given the short duration 
of effect of tDCS, any priming phenomena are only demon-
strable if the two are combined within a short timeframe.
Long-lasting changes in cortical excitability following 
TMS are protocol-dependent but at best their duration lasts 
up to 2 weeks.33 Permanent changes have not been demon-
strated.8,34 Given that all subjects recruited to this study had 
not received TMS treatment for at least 3 months, a priming 
effect is considered by the authors as unlikely.
Regardless of the effect of rTMS on neuronal priming or 
response, pain scores in two of these subjects were lower after 
finishing rTMS therapy and remained lower throughout their 
inclusion in this study. Perhaps this may have represented a 
flooring effect and the limit of the possible treatment effect 
that could be expected in these patients.
All the subjects included in this study had experienced 
pain for at least 3 years. Moreover, these were patients who 
had been through at least one other clinical trial assessing 
treatment for intractable chronic pain, meaning that they had 
failed multiple pharmacological therapies before entry into 
the present study. This group may represent a particularly 
treatment-resistant group of patients with pain. Indeed, their 
mean numerical pain rating scores were remarkably stable 
over the time period of the study. It is difficult to generalize 
as to whether or not patients with more pharmaco-responsive 
pain would respond to tDCS in the same manner.
The identification of the appropriate motor cortex 
stimulation site was based on prior combined TMS pulse 
and EMG activity to map the cortex. We believe that this 
method of localization of motor cortex stimulation target 
is as accurate as possibly available and superior to that 
achieved by the alternative of the EEG 10/20 location 
system. The method described is similar to that reported 
in the recent study by Ihle et al,35 which showed no impact 
of tDCS of the motor cortex on pain processing in 16 
healthy subjects.
interpretation
Recommendations for study design
Apart from recommending that a baseline pain score be 
included at the start of each treatment session, instead of 
at the start of the study alone, the study design could be 
implemented as per the study protocol.
sample size calculation and recommendation for 
definitive study sample size
For calculation of a definitive sample size, we took the high-
est observed SD in our study for differences in pain scores 
between treatments, which was 0.67 (for sham vs cathode) 
at 14 days. The upper 95% CI limit for this SD was 0.99; 
therefore, we can use this as a conservative estimate of the 
SD. We set the minimum clinically important difference 
as a reduction of 15% of our observed mean pain score of 
6.4 after 14 days of sham treatment). A sample size of 13 
patients would give 90% power to detect a difference of 1 
point between two treatments with α=0.05.
The overall sample size of this study was 24 subjects 
recruited and 21 followed through to the end of the study. 
This would suggest that this study is already large enough to 
detect a 15% change in pain scores in the overall trial but that 
sample size for the proportional analysis based on responder 
vs nonresponder subgroups has not been reached.
Conclusion
As our pilot study was already larger than the calculated 
sample size for a definitive study, and our CI estimates 
indicate that all differences were significantly lower than 
the minimum clinically important difference of 1 point, the 
Table 5 Mean values and sDs of baseline and overall treatment on anxiety and depression scores
 Anodal Cathodal Sham
Anxiety N Mean SD N Mean SD N Mean SD
Baseline 21 7.14 2.61 21 7.38 3.34 23 7.48 2.97
Treatment 21 7.33 3.38 21 7.19 2.60 23 7.39 2.81
Depression N Mean SD N Mean SD N Mean SD
Baseline 21 8.86 4.33 21 9.05 5.22 23 8.65 4.51
Treatment 21 8.90 5.05 21 9.14 4.50 23 8.70 4.32
Notes: No significant differences in anxiety or depression scores were demonstrated between baseline and at the end of each treatment period.
 
Jo
ur
na
l o
f P
ai
n 
Re
se
ar
ch
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
8.
25
3.
72
.1
41
 o
n 
16
-J
an
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Journal of Pain Research  2018:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3127
Patient delivered tDcs in chronic neuropathic pain
results of this pilot study do not support the need for a larger 
definitive study using the same stimulation parameters and 
the same electrode configuration.
Efforts have been directed toward better defining the 
precision of current application in tDCS, and advances in 
high-definition tDCS montage configurations may provide a 
more focal stimulation to the M1 cortex. Likewise, utilization 
of alternative parameters, such as transcranial alternating cur-
rent stimulation or online remote confirmation of electrode 
placement, may enhance the design of future experiments. 
It does show that patients can quickly be acquainted with 
using these devices and home-based trials are both feasible 
and realistically achievable.
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